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Abstract
Background: Pre- and early clinical studies on patients with autoimmune diseases suggested that induction of regulatory
T(Treg) cells may contribute to the immunosuppressive effects of glucocorticoids(GCs).
Objective: We readdressed the influence of GC therapy on Treg cells in immunocompetent human subjects and naı ¨ve mice.
Methods: Mice were treated with increasing doses of intravenous dexamethasone followed by oral taper, and Treg cells in
spleen and blood were analyzed by FACS. Sixteen patients with sudden hearing loss but without an inflammatory disease
received high-dose intravenous prednisolone followed by stepwise dose reduction to low oral prednisolone. Peripheral
blood Treg cells were analyzed prior and after a 14 day GC therapy based on different markers.
Results: Repeated GC administration to mice for three days dose-dependently decreased the absolute numbers of Treg cells
in blood (100 mg dexamethasone/kg body weight: 2.861.8610
4 cells/ml vs. 33611610
4 in control mice) and spleen
(dexamethasone: 2.861.9610
5/spleen vs. 95622610
5/spleen in control mice), which slowly recovered after 14 days taper in
spleen but not in blood. The relative frequency of FOXP3
+ Treg cells amongst the CD4
+ T cells also decreased in a dose
dependent manner with the effect being more pronounced in blood than in spleen. The suppressive capacity of Treg cells
was unaltered by GC treatment in vitro. In immunocompetent humans, GCs induced mild T cell lymphocytosis. However, it
did not change the relative frequency of circulating Treg cells in a relevant manner, although there was some variation
depending on the definition of the Treg cells (FOXP3
+: 4.061.5% vs 3.461.5%*; AITR
+: 0.660.4 vs 0.560.3%, CD127
low:
4.061.3 vs 5.063.0%* and CTLA4+: 13.8611.5 vs 15.6612.5%; * p,0.05).
Conclusion: Short-term GC therapy does not induce the hitherto supposed increase in circulating Treg cell frequency,
neither in immunocompetent humans nor in mice. Thus, it is questionable that the clinical efficacy of GCs is achieved by
modulating Treg cell numbers.
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Introduction
Glucocorticoids (GCs) are a class of steroid hormones that bind to
the glucocorticoid receptor, which is present in almost every
vertebrate animal cell [1]. This explains the large variety of
physiological roles played by GCs [2,3]. They are crucial modifier
of the metabolic [4] and immune system [5,6], but are also
important for development [7] as well as for arousal and cognition
[8]. During an immune response, GCs contribute to the termination
of inflammation by both suppressing and enhancing activities of the
immune system [9]. At the level of the innate immune system GCs
induce neutrophilia by increasing polymorphonuclear cell release
from the bone marrow while inhibiting their transmigration to
inflammatorysites[10,11].Atthesametimetheyinduceapoptosisof
basophils and eosinophils [12,13]. In a similar way GCs control the
movement of circulating monocytes while enhancing the phagocy-
totic ability and antigen uptake by the tissue macrophages and
therefore speed up the clearance of foreign antigens and microor-
ganisms [14]. At the level of leukocyte gene expression, a huge
number of proinflammatory cytokines (IL1b,T N F a, IL-6, IL-8, IL-
12, IL-18 etc) and chemokines (both CC and CXC) is strongly
suppressed byGCs,while the anti-inflammatorycytokines IL-10and
TGFb areupregulated [15].Onthe other hand, GCs favor antibody
production by promoting the generation of immunoglobulin
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24345secreting plasma cells [16]. Accordingly, GCs promote the
polarization of naı ¨ve T-cells to a Th2 phenotype while at the same
time promoting an immature dendritic cell phenotype [17]. Both
effects may be in part responsible for a presumed upregulation of
regulatory T (Treg) cells by GCs [18]. In the last decades, it became
clear that Treg cells play an essential role in self-tolerance and for
maintaining immune system homeostasis [19].
Failure of self-tolerance often leads to autoimmune diseases
(AD), with an incidence of 5–10 % of the population [20].
Emergence of autoimmune diseases is not completely understood,
it is however documented that T cells often play an essential role in
their development (e.g. diabetes mellitus type I or type A gastritis
[21]). Some of these autoimmune diseases are probably triggered
by infections (e.g. Guillian Barre ´ syndrome [22,23]), whereas in
others it has been shown that tolerance defects are due to a
decrease in number or defective expression pattern in the Treg cell
population [24,25]. Since more than 60 years GCs are often the
first line therapy in inflammatory and autoimmune responses [26]
and around 30 years ago a connection between GCs and a
‘‘suppressor’’ T cell phenotype was initially shown in vitro [27,28].
In the meantime, a number of different Treg cell populations have
been described [25,29], of which the most studied one expresses
CD4 and high levels of the IL-2 receptor alpha-chain (CD25)
[19,30]. Several additional surface markers have been reported to
discriminate naturally occurring Treg cells from other activated
CD4
+ Th2 cells such as cytotoxic T-lymphocyte antigen 4
(CTLA4) [31,32], the nuclear transcription factor forkhead box
P3 (FOXP3), the activation-inducible tumor necrosis factor
receptor AITR [33] and low expression of the IL-7 receptor
(CD127) [34,35]. Although expression of FOXP3 is considered as
the best tool to define Treg cells by many authors [36,37,38], even
this marker (as all other markers) is not specific to human Treg cells
and can be transiently induced on all effector T cell populations
upon activation.
In 2004, Karagiannidis et al. showed for the first time that GC
treatment in vivo (both systemic and inhaled) induces an increase in
circulating Treg cells (as defined by the FOXP3 and IL-10 mRNA
expression of CD4
+ T cells) in patients with asthma bronchiale
[39]. However, such a positive correlation between GC treatment
and the number of Treg cells in the peripheral blood is still
disputed. In the mouse, Chen et al. could demonstrate that the
synthetic GC dexamethasone increased the proportion of Treg cells
both in peripheral blood and secondary lymphoid organs [40,41].
By contrast, Stock et al. showed the opposite in a mouse model of
asthma [42] as did Wu ¨st et al. in a mouse model of multiple
sclerosis [43]. In humans, several small in vivo studies pointed
towards a positive correlation between administration of GCs and
the frequency of Treg cells in patients with different autoimmune
diseases [44,45,46,47,48,49,50,51,52,53,54]. However, two re-
cently performed larger studies, both including more than 50
patients with asthma bronchiale or autoimmune connective tissue
diseases, respectively, arrived at exactly the opposite conclusion
[55,56]. The fact that these studies do not present a unified picture
of the influence of GCs on Treg cells may be explained by two
aspects. Firstly, there is a huge heterogeneity in the molecular
characterization of Treg cells. Several studies just defined Treg cells
as being CD4
+CD25
high. However, it is evident by now that many
of these cells are not Treg cells but rather activated T cells [57].
Secondly, all but one study analyzed patients with an autoimmune
background and it is likely that different autoimmune diseases
come along with different levels of impairment of Treg cell
frequency and/or function [47,48,51,53]. The only study on
healthy donors so far was performed ex vivo using mixed PBMC
cultures in the presence of dexamethasone, epinephrine and IL-2
[58]. Nonetheless, it has been already shown in mice that IL-2
topple the balance in favor of Treg cells regardeless of GC
treatment [40,41].
Hence, the goal of this study was to determine the influence of
short-term GC therapy, as frequently used in different clinical
scenarios, on circulating Treg cells in immunologically uncompro-
mised mice and humans in vivo.
Methods
Animal experiments
Mice. C57Bl/6 mice were bred in the animal facility at the
University of Go ¨ttingen Medical School, kept in individually
ventilated cages under specific pathogen free conditions and used
at an age of 8–12 weeks. Mice of both sexes were included in the
study. Blood samples were taken by bleedings from the tail, or the
mice were sacrificed using CO2 to obtain the spleen or blood from
the heart. All animal experiments were conducted according to
ethical standards of humane animal care and approved by the
authorities of Lower Saxonia (Niedersa ¨chsisches Landesamt fu ¨r
Verbraucherschutz und Lebensmittelsicherheit, LAVES; approval
ID: 33.14.42502-04-107.08).
GC treatment was performed by intraperitoneal (IP) injection of
0.8 mg/kg, 4 mg/kg, 20 mg/kg or 100 mg dexamethasone
dihydrogen phosphate (Dexa-ratio-pharmH, Ratiopharm, Ulm,
Germany) / kg body weight on three consecutive days [43]. Mice
treated IP with 100 mg/kg were treated for additional 11 days
with oral glucocorticoids with decreasing dosages of water-soluble
dexamethasone (Sigma, Taufkirchen, Germany) added to the
drinking water (days 4 – 7: 10 mg/l, days 8 – 11: 5 mg/l, days 12
– 14: 1 mg/l). The supplemented drinking water was changed
every second day.
Lymphocyte analysis. Lymphocytes were isolated from the
spleen of the mice on days 0, 3 and 14 by passing the freshly
isolated organs through a 40 mm Nylon mesh, washed in FACS-
Buffer (PBS with 0.5% BSA and 0.05% NaN3), erythrolyzed and
counted. Absolute cell numbers in blood were determined by flow
cytometric analysis of a defined blood volume. Analysis of
splenocytes and blood lymphocytes by six-color flow-cytometry
was performed using a FACS Canto II device (BD Biosciences,
Heidelberg, Germany) in combination with FlowJo software.
Monoclonal antibodies directed against mouse leukocyte specific
molecules were obtained from BD Biosciences unless otherwise
indicated (clone name in brackets): CD3 e (145-2C11), CD4
(RM4-5), CD8a (53–6.7), CD25 (PC61), TCRab (H57-597), GR-
1 (RB6-8C5), B220 (RA3-6B2), FoxP3 (FJK-16S; eBiosciences,
Frankfurt, Germany). The antibodies were directly labeled with
FITC, PE, PerCP, PE-Cy7, Cy5, APC or APC-Cy7, respectively.
Analysis of the suppressive activity of Treg cells in
vitro. CD4
+CD25
+ regulatory T (Treg) cells and conventional
CD4
+CD25
2 helper T (Th) cells serving as indicator cells were
purified from spleens of C57BL/6 mice using the CD4
+CD25
+
Regulatory T Cell Isolation Kit (Miltenyi Biotech, Bergisch Gladbach,
Germany). Th cells (5610
4 cells / well) and different amounts of
Treg cells were cocultured with c-irradiated antigen-presenting
cells (30 Gy, 10
5 cells / well) for 48 hrs in RPMI 1640 medium
supplemented with 10 % FCS and 1% Pen/Strep in 96-well U-
bottom plates. Polyclonal stimulation was achieved by adding Con
A (2,5 mg/ml) into the cultures. Water-soluble dexamethasone
(Sigma, Taufkirchen, Germany) was added to a final
concentration of 5 nM where indicated. Unstimulated and
stimulated Th cells and Treg cells alone served as controls.
Proliferation was assessed by measuring
3H-TdR (Hartmann
Analytics, Braunschweig, Germany) incorporation (37 kBq / well)
Glucocorticoids and Regulatory T Cells
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was harvested onto Filtermat A glassfibre filters and the
radioactivity was quantified using a MicroBeta
2 ß-scintillation
counter (Perkin Elmer, Rodgau, Germany). In addition,
supernatants were collected from cultures after 48 hrs and
Interleukin-2 levels were measured using a commercially
available ELISA kit (BioLegend, San Diego/CA, USA)
according to the manufacturers’ instructions.
Human experiments
Patients. 16 patients (10 males and 6 females) with acute
hearing loss were routinely treated in the Department of
Ophthalmology and Otolaryngology of the University Hospital
of Wu ¨rzburg using a modified ‘‘Stennert scheme’’ (only GCs
without pentoxifyllin as clinically indicated). All individuals were
otherwise healthy and fulfilled the following inclusion criteria: age
.18 years (mean patient age was 35.8613 years), no GCs or other
immunosuppressive therapy in the last 8 weeks, no suspected
endogenous GC excess and no evidence for any malignant or
autoimmune diseases or any acute or chronic infections. All
patients gave written informed consent and the study was
approved by the ethic committee of the University of Wu ¨rzburg
(Ethik-Kommission der Medizinischen Fakulta ¨t der Universita ¨t
Wu ¨rzburg, Amendment 1 zu Studien-Nr. 83/05). Prednisolone
was administered according to the following regimen: day 1–3:
250 mg intra venous (IV), day 4: 150 mg IV, day 5–9: 100 mg per
os (P.O.), day 10–11: 75 mg P.O., day 12: 50 mg P.O., day 13:
20 mg P.O. and day 14: 10 mg P.O.
Lymphocyte analysis. Before the first injection of
prednisolone (day 0) and at the end of the 14 day treatment
period 5 ml EDTA and 20 ml heparinized blood were taken from
the patients. The EDTA blood was analyzed in the central
laboratory of the University Hospital of Wu ¨rzburg for a complete
blood count with white blood cell differential. The heparinized
blood was diluted with 20 ml phosphate buffer saline (PBS).
Subsequently, the diluted blood was applied to a Ficoll hypaqueH
gradient and separated via centrifugation at 400 G for 30 minutes
[59]. The peripheral blood mononuclear cells (PBMC) were
pipetted from the interface and washed twice with PBS. For a
detailed characterization of cellular changes induced by GCs, the
PBMCs were stained according to manufacturers’ protocols using
six different sets of monoclonal antibodies directed against various
surface molecules (clone numbers in brackets): Set 1: CD3
(UCHT1), CD14 (M5E2), CD19 (HIB19); Set 2: CD8 (SK-1),
CD25 (M-A251), CTLA-4 (BNI3); Set 3: CD4 (RPA-T4), CD25
(M-A251), CD127 (hIL-7R-M21); Set 4: CD4 (RPA-T4), CD25
(M-A251), AITR (eBioAITR); Set 5: CD4/CD 25 (RPA-T4/
BC96) and staining control Set 6: no antibodies. Subsequently, the
cells which had been stained with the surface markers of sets 5 and
6 were fixed and permeabilized according to the manufacturer’s
instructions followed by intracellular staining with rat-anti-FOXP3
(PCH101) and the appropriate isotype control antibody (eBR2a).
The antibodies used in the sets 1 to 4 were obtained from BD
Biosciences (Heidelberg, Germany) and those in the sets 5 and 6
from eBiosciences (Frankfurt, Germany). All antibodies were
directly labeled with FITC, PE and APC. Three-color flow
cytometry measurements were performed using a FACS Calibur
and data analysis was done by using CellQuest pro software (both
BD Biosciences, Heidelberg, Germany).
Statistics
Results are depicted as mean 6 standard deviation (SD). For
statistical analysis a repeated measures Anova followed by
Bonferroni comparison test was performed using Prism v.4.b.
software for Macintosh (GraphPad Software Inc., La Jolla, CA,
USA). A P value ,0.05 was considered statistically significant.
Results
Systemic high-dose GC treatment of mice reduces Treg
cells numbers in peripheral blood and spleen
We have chosen a protocol for GC treatment of mice mimicking
steroid regimens widely applied to human patients. Whilst therapy
of acute relapses in multiple sclerosis patients for example consists of
several repeated injection of high-dose GC followed by a taper
[60,61], lower concentrations of GC are used to treat rheumatoid
arthritis or asthma patients. Our protocol has been further adapted
to consider differences between mice and humans in terms of
pharmacokinetics and handling by employing IP injections of
dexamethasone [43,62]. The number of CD4
+ T cells in the blood
of the mice decreased in a dose-dependent manner dropping to
levels below 10% of control animals after 3 days of IP treatment
with 100 mg/kg dexamethasone (Figure 1A). CD4
+ T cell numbers
remained low even after oral steroid taper (Table 1 and Figure 1A).
The number of Treg cells defined as CD4
+CD25
highFOXP3
+ T cells
also decreased in a dose-dependent manner after the 3 day of GC
therapy and did not recover after an additional 11 days of oral
treatment (Figure 1C). Importantly, also the percentage of FOXP3
+
Treg cells decreased amongst the CD4
+ T cell population with the
GC doses applied, and did not recover at day 14 (Figure 1E).
In the spleen of the same mice the situation was slightly different.
Although the absolute number of CD4
+ T cells also strongly and
dose-dependently decreased after the 3 days IP treatment (Table 1
and Figure 1B), the cell numbers partially recovered during the
phase of oral GC taper (Figure 1B). The same situation applies to
the FOXP3
+ Treg cells, the number of which decreased after 3 days
andslightlyrecoveredafterthe14daysofGCtreatment(Figure1D).
Consequently, the relative proportion of Treg cells amongst the
CD4
+ T cell population significantly decreased (Figure 1F) after the
high-dose systemic GC treatment. Interestingly, the percentage of
Treg cells recovered after the additional 11 days of oral taper to
values comparable to those before treatment (Figure 1F).
GC treatment does not impact the suppressive capacity
of Treg cells in vitro
Besides altering the absolute or relative numbers of Treg cells in
blood and peripheral lymphoid organs, it is also conceivable that
GC impact the suppressive capacity of Treg cells. This functional
characteristic is best studied in vitro. Furthermore, a concentration
of 5 nM dexamethasone was chosen since pilot experiments had
revealed that this already leads to a significant regulation of T cell
function while at the same time proliferation is only slightly
affected (data not shown). To assess whether GC alter the
functional properties of Treg cells in vitro, we performed a standard
suppression assay in the absence or presence of dexamethasone by
adding decreasing amounts of Treg cells to ConA-stimulated Th
cells serving as indicator cells. The activity of the Th cells was
assessed by analyzing proliferation on the basis of
3H-TdR
incorporation (Figure 2A) as well as by determining IL-2
production (Figure 2B). Importantly, addition of dexamethasone
into the culture did not significantly alter the suppressive capacity
of Treg cells, neither in terms of proliferation (42.7615.5 % at 1:1
Treg:Th ratio in control cells vs 32.0613.7 % in cells treated with
dexamethasone; n.s.) nor in terms of IL-2 secretion (30.764.5 % at
1:1 Treg:Th ratio in control cells vs 30.061.0 % in cells treated
with dexamethasone; n.s.) (Figure 2). This suggests that - at least in
vitro - GCs do neither positively nor negatively influence the
functional properties of Treg cells.
Glucocorticoids and Regulatory T Cells
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24345GCs have little impact on the relative frequency of
circulating Treg cells in immunologically uncompromised
human subjects
The 14 days of prednisolone administration to human subjects,
none of which suffered from immunological diseases, induced a
doubling of circulating leukocytes (Table 2). As expected, this was
mainly attributed to a significant increase in circulating neutro-
phils. In addition, the number of monocytes also doubled and the
number of lymphocytes increased by 30%, while the numbers of
basophils and eosinophils remained unaltered. Of note, the
Figure 1. Modulation of CD4
+ T cells and Treg cells by GCs in mice. Peripheral blood (A, C, E) and spleen (B, D, E) cells from C57BL/6 mice were
analyzed by flow cytometry before, 3 days after IP treatment with different dosages of dexamethasone and 14 days after IP treatment with 100 mg/
kg dexamethasone followed by oral taper. The absolute numbers of CD4
+ T cells (A, B) and CD4
+CD25
highFOXP3
+ Treg cells (C, D) were assessed and
the relative frequency of Treg cells amongst all CD4
+ T cells was calculated (E, F); *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0024345.g001
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remained largely unchanged with the exception of the eosinophils
that decreased slightly (Table 2).
With regard to the T cell population, the 14 days of GC
administration induced a 1.5-fold increase in the number of CD3
+
T cells from 1565.8610
5 to 23610610
5 cells/ml (p,0.001;
Table 2) due to an increase in CD8
+ T cell numbers (462.5610
5
to 5.863.1610
5 cells/ml; p,0.001) as well as CD4
+ cell numbers
(1164.0610
5 to 1867.7610
5 cells/ml; p,0.001; Figure 3A). In
contrast, the relative frequency of all T cell subpopulations
remained unaffected (58611 to 5869.0% T-cells in PBMC;
24.569.0% to 24.367.5% CD8
+ T cells and 75.569.0% to
75.767.5% CD4
+ T cells within the T cell population; Figure 3B).
The Treg cells, being a subpopulation of the CD4
+ T cells, followed
the positive trend in absolute cell numbers, however, depending on
their molecular characterization, the amplitude differed (Figure 4).
The number of Treg cells increased only slightly when defined as
FOXP3
+ (62635610
3 to 82647610
3 cells/ml; p,0.05; Figure 3C
and 4A, B) or AITR
+ (8.966.8610
3 to 1069.0610
3 cells/ml; n.s.;
Figure 3E and 4C, D), whereas the CD127
low and the CTLA4 Treg
cells doubled from 56624610
3 to 100660610
3 cells/ml
(p,0.001; Figure 3G and 4E, F) and from 160670610
3 to
3006200610
3 cells/ml (p,0.05; Figure 3I and 4G, H), respec-
tively. The frequency of the Treg cells amongst the CD4
+ T cells also
varied depending on the molecular characterization. Whereas the
frequency of FOXP3
+ and AITR
+ Treg cells within the CD4
+ T cell
population slightly decreased after GC treatment from 4.061.5 to
3.461.5% (p,0.05; Figure 3D) and 0.660.4% to 0.4560.3% (n.s.;
Figure 3F), respectively, their percentages did not increase in a
relevant manner from 4.061.3% to 563.0% (p,0.05; Figure 3H)
and from 13.8611.5% to 15.6612.5% (n.s.; Figure 3J) when the
Treg cells were defined as CD127
low and CTLA4
+, respectively.
Discussion
Treg cells exert potent suppressive effects on the immune system
through a plethora of different mechanisms. It has been previously
reported that the frequency of Treg cells is essential for the
prevention of exaggerated inflammation and autoimmunity
[24,25], and some studies suggested that Treg cells are induced
by GCs both in mice and humans [41,50]. It was hypothesized
that this is due to the differential responsiveness of this specialized
T cell subpopulation to GCs [40]. However, the respective
Table 1. Lymphocyte counts and percentages in the blood and spleen of mice before and after GC therapy in vivo.
cell numbers (cells / ml ± SD)
before therapy 3d after IP therapy with dexamethason (mg/kg) 14d after therapy
Blood 0.8 4 20 100
CD4
+ cells 37.3610
4618.8610
4 26.2610
4618.9610
4 18.8610
4615.7610
4 14.2610
466.2610
4 2.8610
461.8610
4 6.3610
461.8610
4
FOXP3
+ cells
* 2.6610
461.3610
4 1.3610
461.0610
4 1.0610
460.9610
4 0.3610
460.3610
4 0.07610
460.05610
4 0.22610
460.12610
4
%FOXP3 in
CD4
+ cells
7.261.4 4.860.8 560.7 3.161.7 2.760.8 2.960.7
spleen cell numbers (cells / spleen 6 SD)
CD4
+ cells 12.6610
663.8610
6 6.0610
662.2610
6 2.5610
661.6610
6 1.6610
661.5610
6 0.3610
660.2610
6 3.0610
661.4610
6
FOXP3
+ cells
* 1.4610
660.3610
6 0.7610
660.3610
6 0.2610
660.1610
6 0.1610
660.1610
6 0.02610
660.01610
6 0.4610
660.2610
6
%FOXP3 in
CD4
+ cells
11.162.9 10.5361.3 8.761.0 6.762.7 6.661.9 12.06.1
*= as subpopulation of CD4
+CD25
high cells.
{= % out of CD4
+ cells 6 SD.
doi:10.1371/journal.pone.0024345.t001
Figure 2. Effect of GC on the function of Treg cells in vitro. Th cells
(5610
4 cells / well) were incubated with Tregcells at different ratios in the
presenceofirradiatedAPC(30 Gy,10
5 cells/well)andConA(2,5 mg/ml)
for 48 hrs, either with dexamethasone (dex, 5 nM) or without it (con).
RestingThcellsaswellasThandTregcellsstimulatedwithConAservedas
controls. Proliferationwas determinedby
3H-TdRincorporationduringan
additional 16 hrs culture period (A), IL-2 levels were directly measured in
the supernatants by ELISA (B). All values were normalized to stimulated
Th cells treated with or without Dex, respectively. In both panels the
combined data of three independent experiments are depicted.
doi:10.1371/journal.pone.0024345.g002
Glucocorticoids and Regulatory T Cells
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rather in combination with potent T-cell inducers like IL-2 or
vitamin D3, or they were performed on vaccinated or immuno-
defficient mice [41,63]. To reassess the impact of GC therapy on
Treg cells in mice in the context of steroid monotherapy, we
applied a protocol with increasing dosages of 0.8 to 100 mg/kg
dexamethasone IP for 3 days. This therapy led to a dose
dependant decrease of CD4
+ T cells in peripheral blood and
spleen. Surprisingly, the decrease in the number of Treg cells was
even more pronounced than the number of total CD4
+ T cells.
This is in agreement with the data of Stock et al. [42] who show in a
mouse asthma model that GCs induce Treg cell deficiency, which
aggravates the long-term course of the allergic disease. It is also in
line with the data of Wu ¨st et al. [43] who reported a relative
decrease of Treg cell numbers in a mouse model of multiple
sclerosis following high-dose GC therapy. During the additional 11
days of oral taper (from 10 mg/l to 1 mg/l) the low T cell
numbers and frequencies in the blood persisted whereas the
number of CD4
+ T cells in the spleen slightly recovered and the
proportion of Treg cells even reached similar levels compared to
before the therapy. The observed differences between peripheral
blood and spleen might suggest that while under GC therapy no
new Treg cells are being produced by the thymus, they are
constantly generated de novo in the secondary lymphatic organs.
This corroborates data showing that GCs induce an immature
dendritic cell (DC) phenotype in the periphery capable of
transforming naı ¨ve T cells into Treg cells [64]. We therefore
postulate that high-dose CG therapy in the mouse induces massive
apoptosis of CD4
+ T cells, that Treg cells show an increased
sensitivity to GCs, and that a prolonged lower dose of GCs favors
their tolerogenic DC-induced regeneration in the periphery.
Our finding that the absolute and relative numbers of Treg cells
in blood and spleen are decreased by GC treatment in vivo does not
necessarily exclude that the functional properties of the Treg cells
are altered. However, we found that the suppressive capacity of
Treg cells was indistinguishable in the presence or absence of GC
at least in vitro. Neither inhibition of Th cell proliferation nor
repression of their IL-2 production by Treg cells was different when
dexamethasone was added to the cultures. Although we cannot
fully exclude that Treg cell function in vivo is affected by GC
treatment, our in vitro results nevertheless strongly argue that GC
do not impact the functional properties of Treg cells directly.
In the human subjects, 14 days of prednisolone administration
in a dosage used for the treatment of many common diseases led to
strong blood leukocytosis, mainly due to the already described
increase in circulating neutrophils and monocytes but to a minor
extent also in lymphocytes. Of note, T cells as well as their CD4
+
and CD8
+ subpopulations increased at the same rate. On average,
the numbers of CD4
+CD25
high Treg cells increased independently
of additional markers used for their identification. However, this
change was only significant when using FOXP3
+, CD127
low and
CTLA4
+ as definition of Treg cells but not AITR
+. Similarly, the
frequency of FOXP3
+ Treg cells within the CD4
+ T cell population
decreased slightly, whereas the relative number of CD127
low Treg
cells increased and the one of AITR
+ and CTLA4
+ Treg cells
showed no relevant changes concerning the Treg/CD4
+ T cell
ratio. We therefore conclude that GCs have no relevant impact on
the frequency of circulating Treg cells. However, our study also
indicates that the outcome of the analysis of Treg cells in peripheral
blood of human subjects depends - at least in part - on the markers
used for their molecular characterization. This could explain -
amongst others - the partially contradictory results published
before. Considering FOXP3 expression, the most accepted marker
of Treg cells, in our human cohort, the GC taper treatment seems
to induce an increase in Treg cell numbers but at the same time an
even stronger increase in CD4
+ T cells. This even results in a
significant reduction of the relative frequency of Treg cells as
compared to the rest of the circulating CD4
+ T cells and thereby
confirms our results obtained in mice. Thus, our findings call the
hypothesis that GCs exert some of their immunosuppressive
capacity by inducing Treg cells into question. Therefore, it is
tempting to speculate that GCs rather modify cell-cell interactions
Table 2. Blood lymphocyte counts in immunocompetent human subjects before and after GC therapy in vivo.
cell numbers (cells/ml ± SD) frequency (% ±SD)
cell type before therapy after therapy p value before therapy after therapy p value
leukocytes 7.363.0610
6 13.064.2610
6 p,0.001 - - -
neutrophils 4.662.6610
6 9.363.7610
6 p,0.001 60.4611.6
# 68.0610.3
# n.s.
basophils 1.764.0610
4 7.063.0610
3 n.s. 0.260.5
# 0.160.3
# n.s.
eosinophils 1.461.4610
5 1.361.0610
5 n.s. 2.562.6
# 0.960.7
# p,0.05
monocytes 5.061.5610
5 8.562.6610
5 p,0.001 7.562.3
# 6.561.7
# n.s.
lymphocytes 2.060.7610
6 3.061.3610
6 p,0.01 28.768.5
# 24.069.6
# n.s.
CD3
+ cells 1.560.6610
6 2.361.0610
6 p,0.001 58.0611.0
1 58.069.0
1 n.s.
CD8
+ cells 4.062.5610
5 5.863.1610
5 p,0.001 24.569.0
$ 24.367.5
$ n.s.
CD4
+ cells 11.064.0610
5 18.067.7610
5 p,0.001 75.569.0
$ 75.767.5
$ n.s.
FOXP3
+ cells
* 6.263.5610
4 8.264.7610
4 p,0.05 4.061.5
{ 3.461.5
{ p,0.05
AITR
+ cells
* 8.966.8610
3 10.069.0610
3 n.s. 0.660.4
{ 0.560.3
{ n.s.
CD127
low cells
* 5.662.4610
4 10.066.0610
4 p,0.001 4.061.3
{ 5.063.0
{ p,0.05
CTLA4
+ cells
* 1.660.7610
5 3.062.0610
5 p,0.05 13.8611.5
{ 15.6612.5
{ n.s.
*= as subpopulation of CD4
+CD25
high cells.
#= % out of leukocyte cells 6 SD.
1= % out of PBMC 6 SD.
$= % out of CD3
+ cells 6 SD.
{= % out of CD4
+ cells 6 SD.
doi:10.1371/journal.pone.0024345.t002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24345Figure 3. Modulation of CD4
+ T cells and Treg cells by GCs in humans. Peripheral blood cells from acute hearing loss patients before and 14
days after prednisolone treatment were analyzed by flow cytometry and the absolute numbers (A, C, E, G, I) and the frequency (B, D, F, H, J) of CD4
+ T
cells (A, B) and Treg cells (CD4
+CD25
high and FOXP3
+ (C, D), AITR
+ (E, F), CD127
low (G, H) or CTLA4
+ (I, J)) were assessed; *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0024345.g003
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24345Figure 4. Flow cytometric analysis of Treg cells according to different markers. Peripheral blood from one representative hearing-loss
patient treated for 3 days (A, C, E, G) and 14 days (B, D, F, H) with glucocorticoid regimen was analyzed for the presence of regulatory T cells according
to the following markers: CD4
+ CD25
high and FOXP3
+ (A, B), AITR
+ (C, D) CD127low (E, F) and CTLA4
+ (G, H). Only CD4
+ cells are depicted and the
percentages indicate the relative frequency of Treg cells within this subpopulation.
doi:10.1371/journal.pone.0024345.g004
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frequency.
Our results are seemingly in contrast to several previously
published in vivo studies that showed an increased number of Treg
cells and, even more importantly, an elevated T
reg/CD4
+ T cell
ratio in humans treated with GCs [44,45,50]. However, as
mentioned before, most of these studies were performed in patients
either suffering from hyperimmune or autoimmune diseases
[51,52,53,54]. Interestingly, the same studies show a deficiency
of Treg cells in the same patients, probably due to thymic
dysfunction, and thus the GC treatment seems to only restore their
numbers to levels of healthy subjects. Based on our data we
therefore hypothesize that GCs induce a tolerogenic environment
in these patients leading to the generation of Treg cells in the
secondary lymphatic organs which compensates for the thymic
dyfunction by creating an apparent advantage of the Treg cells as
compared to the rest of the T cells. However, the reconstitution of
the Treg cells will last only until the therapy ends and the de novo
generated Treg cells are recycled, which might explain the short-
lived benefit and the high relapse rate described after GC therapy
[65].
Our study has strengths and limitations. Firstly, the individuals
of our study cohort consisting of patients with acute hear loss are
most likely immunocompetent although the exact cause of the
acute hear loss is unknown [66,67]. Secondly, the dosage of GCs
in our prospective study was chosen rather arbitrarily and might
have impact on the results. Of note, 5 of 7 patients tested on day
14 showed impaired adrenocortical function as measured by
ACTH stimulation test (data not shown). In the case of our mouse
study, we administered a regimen consisting of increasing doses of
dexamethasone [43], whereas in the human study we used the
standard dosage for hear loss, which is also utilized for several
autoimmune diseases such as lupus erythematosus [68] or
idiopathic thrombocytopenic purpura [69]. Thirdly, we analyzed
only selected time points and it thus remains open whether the
effects that we see are only transient and would be different after
shorter or longer time periods of GC treatment. Finally, we used
several markers for Treg cell characterization, acknowledging the
fact that there is still no consensus on the best definition of Treg
cells in humans. However, despite the results being slightly
different between each Treg cell characterization, the effect on the
relative frequency of circulating Treg cells in general is weak.
In conclusion, short-term GC therapy did not induce the
expected increase in the frequency of circulating Treg cells, neither
in immunocompetent human subjects nor in mice. In the same
time GC treatment in vitro did not have any direct effect on the
functional ability of the Treg cells. Thus, it is doubtful whether GCs
exerts their immunosuppressive effects via influencing the
functionality and the (relative) number of Treg cells in blood and
spleen.
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